Zydus Lifesciences Limited (ZYDUSLIFE) announced that the USFDA conducted an onsite inspection of the pharmacovigilance and post marketing surveillance system at the company’s office based in New Jersey, USA. The inspection, which took place from 22nd to 25th September 2026, concluded with nil observations. This positive outcome may be considered a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Inspection Details

The USFDA inspection focused on the company’s pharmacovigilance and post marketing system. The team evaluated the company’s processes and compliance with regulatory standards. Zydus Lifesciences Limited’s robust framework was validated as the inspection resulted in no observations.

Significance of the Outcome

The nil observations from the USFDA inspection signify the company’s commitment to maintaining high standards in pharmacovigilance and post marketing surveillance. This outcome is crucial as it reinforces the company’s regulatory compliance and enhances its reputation in the pharmaceutical sector. Moreover, it indicates that the company’s systems are functioning effectively without any regulatory gaps.

Future Implications

As a result of this positive inspection, Zydus Lifesciences Limited can continue to operate with confidence in its regulatory compliance. This may also positively influence investor sentiment and stakeholder trust. The company remains dedicated to upholding stringent quality and safety standards in its pharmaceutical operations.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus rises 9.3% over three months, with buying pressure holding steady. The PEG of 0.72 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. Both the business and the stock move in the right direction. Revenue grows at 16.5%, profits at 37.0%, and the PEG sits at 0.72 — below its growth rate. That combination is rare. Check Fundamentals of Zydus Lifesciences Limited.

Jagsonpal Pharmaceuticals Limited (Jagsonpal) today announced the execution of a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited (Group Pharma) for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The transaction involves an initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of up to ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores. The transaction is expected to be completed on or before 01 November, 2026, subject to fulfilment of conditions precedent and other terms stipulated under the BTA.

Strategic Growth Move

This acquisition marks another meaningful step in Jagsonpal’s growth journey. It strengthens the company’s pharmaceutical portfolio and expands its presence across complementary therapeutic segments, especially in women healthcare, while remaining consistent with its asset-light and focused approach to growth. Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: ‘The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments especially in women healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.’

Seamless Integration

Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: ‘We are delighted to welcome this portfolio and the employees of the business into our organization, and are fully committed to ensuring their smooth and seamless integration. We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.’

The transaction is subject to the fulfilment of applicable conditions precedent and other customary closing conditions as set out in the BTA. Think Law Advisors represented Jagsonpal as their legal Advisors while Tatva Legal advised Group Pharma on the transaction.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Jagsonpal posts a 0.9% three-month gain, but softens in the last few weeks. The PEG of 1.95 limits the upside. The stock does not come cheap. Revenue grows at 6.7% and profits at 17.3% CAGR. The numbers are respectable but unlikely to re-rate the stock. The stock gives back 3.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 0.9% in three months on 6.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Jagsonpal Pharmaceuticals Limited.

Indegene Limited (INDGN) recently hosted its eighth edition of the Digital Summit, focusing on operationalizing AI to deliver enterprise outcomes in the life sciences sector. The event, held on September 22 at the National Constitution Center in Philadelphia, brought together over 200 senior leaders to discuss translating AI investments into measurable business impact.

Operationalizing AI for Business Impact

The summit’s theme, ‘From Promise to Performance: Operationalizing AI for Enterprise Outcomes,’ emphasized the need for a next-generation operating model in life sciences. Speakers highlighted how AI can connect data, intelligence, and evidence to enable strategic decisions, drive successful product launches, and accelerate drug discovery and clinical research.

Recognition at VITAL Awards

The summit also hosted the second edition of the VITAL Awards, recognizing leaders delivering measurable industry impact. Honorees were named in Organizational Impact and Market Impact categories, alongside special awards for Transformational Leadership. Notable recipients included Brian Cantwell and Agam Upadhyay for Transformational Leadership, and Saket Malhotra for Organizational Impact.

Manish Gupta, Chairman and CEO of Indegene, remarked, ‘Life sciences has built an extraordinary legacy of helping people live longer, healthier lives. But increasingly specialized therapies and precision medicines cannot be supported by operating models designed for an era of mass promotion. The opportunity now is to thoughtfully rewire the enterprise around AI, augment our people, and build systems that are smarter, faster, and more responsive, turning the promise of technology into measurable performance for patients, physicians, and the business.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Indegene gains 15.5% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Buyers show up with 2.1x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 15.5% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.